At the time of writing, NovoCure Ltd [NVCR] stock is trading at $21.96, up 4.57%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NVCR shares have gain 0.69% over the last week, with a monthly amount drifted -13.48%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on December 02, 2024, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $30 from $18. Previously, H.C. Wainwright upgraded its rating to Buy on October 16, 2024, and elevated its price target to $30. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to a Overweight but $45 remained the price target by the analyst firm on August 08, 2023. SVB Securities started tracking with a Outperform rating for this stock on August 04, 2023, and assigned it a price target of $51. In a note dated July 31, 2023, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $33.
For the past year, the stock price of NovoCure Ltd fluctuated between $11.70 and $34.13. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $21.96 at the most recent close of the market. An investor can expect a potential return of 36.61% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
According to NovoCure Ltd [NASDAQ:NVCR], the company’s sales were 577.74M for trailing twelve months, which represents an 21.81% jump. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.41 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.87.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.25 points at the first support level, and at 20.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.48, and for the 2nd resistance point, it is at 23.01.
Ratios To Look Out For
It is important to note that NovoCure Ltd [NASDAQ:NVCR] has a current ratio of 1.49. As well, the Quick Ratio is 1.44, while the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 4.11, the price to book ratio is 6.58.
Transactions by insiders
Recent insider trading involved Paravasthu Mukund, Chief Operating Officer, that happened on Jan 11 ’25 when 2160.0 shares were sold. Officer, MUKUND PARAVASTHU completed a deal on Jan 13 ’25 to buy 2160.0 shares. Meanwhile, Officer WILHELMUS C. GROENHUYSEN bought 0.27 million shares on Jan 02 ’25.
